Biolink - to investigate and determine if treatment with ramatroban, administered for 28 days to hospitalized, non-ICU patients with covid-19 pneumonia, reduces the risk of subsequent development of…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50122C00068
- Awardee
-
Biolink Life Sciences, Inc. UEI GUSQRGKRZ4C9
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $207,236
Award facts
- Opportunity
-
- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement Solicitation · BAA20100SOL0002 · Posted Feb 3, 2020
- Contract value 100% obligated
- $207,236.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 100 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Cary, NC 27513, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$242,764 | |
| Other Administrative Action | -$300,000 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $750,000 |
About this award
This is a $207,236 firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Biolink Life Sciences, Inc., a woman-owned small business. The contract is part of the Biolink program, which is a randomized, double-blinded, placebo-controlled, parallel-design, multi-center, adaptive study to investigate whether treatment with ramatroban for 28 days reduces the risk of subsequent development of post-acute sequelae of SARS-CoV-2 (PASC) in hospitalized, non-ICU patients with COVID-19 pneumonia over the ensuing 11 months. The contract was awarded under a Broad Agency Announcement, and no set-aside was used.
Description
Biolink - to investigate and determine if treatment with ramatroban, administered for 28 days to hospitalized, non-ICU patients with covid-19 pneumonia, reduces the risk of subsequent development of pasc over the ensuing 11 months. Provided data
Quick answers
Who was awarded contract 75A50122C00068?
75A50122C00068 was awarded to Biolink Life Sciences, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 26, 2022.
How much is contract 75A50122C00068 worth?
The government has obligated $207,236 on 75A50122C00068.
Was contract 75A50122C00068 competed?
The extent of competition for 75A50122C00068 was competed under sap. The government received 100 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award